World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0000725069
Reproduction Date:

Title: Famotidine  
Author: World Heritage Encyclopedia
Language: English
Subject: List of drugs: Fa, Antihistamine, Roxatidine acetate, H2 receptor antagonists, Drugs for peptic ulcer and GORD
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Trade names Pepcid
Licence data US FDA:
Legal status
  • Pharmacist only S3/S4(AU), General Availability (OTC)(UK),
    Over the Counter(US)
Routes of
Oral (tablet form)
Pharmacokinetic data
Bioavailability 40-45% (Oral)[1]
Protein binding 15-20%[1]
Metabolism hepatic
Biological half-life 2.5-3.5 hours[1]
Excretion Renal (25-30% unchanged [Oral])[1]
CAS Registry Number  Y
ATC code A02
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C8H15N7O2S3
Molecular mass 337.449 g/mol

Famotidine (l trade name Pepcid) is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. Unlike cimetidine, the first H2 antagonist, famotidine has no effect on the cytochrome P450 enzyme system, and does not appear to interact with other drugs.[2]


  • Medical uses 1
    • Preparations 1.1
  • Side effects 2
  • History 3
  • Research 4
  • See also 5
  • References 6

Medical uses

Famotidine is also given to dogs and cats with acid reflux.[14] Famotidine has been used in combination with an H1 antagonist to treat and prevent urticaria caused by an acute allergic reaction.[15]


Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States and Canada, 10 mg and 20 mg tablets, sometimes in combination with an antacid,[16][17] are available OTC. Larger doses still require a medical prescription.

Side effects

Side effects associated with famotidine use include headache, dizziness, and constipation or diarrhea.[18]


Famotidine was developed by Yamanouchi Pharmaceutical Co.[19] It was licensed in the mid-80s by Merck & Co.[20] and is marketed by a joint venture between Merck and Johnson & Johnson. The imidazole ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be 9 times more potent than ranitidine, and 32 times more potent than cimetidine.[21]

It was first marketed in 1981. Pepcid RPD orally disintegrating tablets were released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz) or Quamatel (Gedeon Richter Ltd.).

In the United States and Canada, a product called Pepcid Complete, which combines famotidine with an antacid in a chewable tablet to quickly relieve the symptoms of excess stomach acid, is available. In the UK, this product was known as Pepcidtwo prior to its discontinuation in April 2015.[22]

Famotidine suffers from poor bioavailability (50%), as it is poorly soluble in the low pH of the stomach. When used in combination with antacids, it promotes local delivery of these drugs to the receptor of the parietal cell wall. Therefore, researchers are developing innovative formulations of tablets, such as gastroretentive drug delivery systems. Such tablets are retained in the stomach for a longer period of time, thereby improving the bioavailability of drugs. Local delivery also increases bioavailability at the stomach wall receptor site and increases the efficacy of drugs to reduce acid secretion.[23]


Famotidine has been investigated as an adjunct in treatment-resistant schizophrenia. In one trial, it caused a 10% reduction in schizophrenic symptom severity in treatment-resistant patients.[24]

See also


  1. ^ a b c d Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.
  2. ^ Humphries TJ, Merritt GJ (August 1999). "Review article: drug interactions with agents used to treat acid-related diseases" (pdf). Aliment. Pharmacol. Ther. 13 (Suppl 3): 18–26.  
  3. ^ Kanayama, S (January 1999). "[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].". Nihon rinsho. Japanese journal of clinical medicine 57 (1): 153–6.  
  4. ^ Soga, T; Matsuura, M; Kodama, Y; Fujita, T; Sekimoto, I; Nishimura, K; Yoshida, S; Kutsumi, H; Fujimoto, S (August 1999). "Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?". Journal of gastroenterology 34 (4): 435–40.  
  5. ^ Borody, TJ; Andrews, P; Fracchia, G; Brandl, S; Shortis, NP; Bae, H (October 1995). "Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.". Gut 37 (4): 477–81.  
  6. ^ Hu, FL; Jia, JC; Li, YL; Yang, GB (2003). "Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.". The Journal of international medical research 31 (6): 469–74.  
  7. ^ Kirika, NV; Bodrug, NI; Butorov, IV; Butorov, SI (2004). "[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].". Terapevticheskii arkhiv 76 (2): 18–22.  
  8. ^ Fujiwara, Y; Higuchi, K; Nebiki, H; Chono, S; Uno, H; Kitada, K; Satoh, H; Nakagawa, K; Kobayashi, K; Tominaga, K; Watanabe, T; Oshitani, N; Arakawa, T (June 2005). "Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.". Alimentary pharmacology & therapeutics. 21 Suppl 2: 10–8.  
  9. ^ La Corte, R; Caselli, M; Castellino, G; Bajocchi, G; Trotta, F (June 1999). "Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.". Drug safety 20 (6): 527–43.  
  10. ^ Laine, L; Kivitz, AJ; Bello, AE; Grahn, AY; Schiff, MH; Taha, AS (March 2012). "Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.". The American journal of gastroenterology 107 (3): 379–86.  
  11. ^ Escolano, F; Castaño, J; López, R; Bisbe, E; Alcón, A (October 1992). "Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery.". British journal of anaesthesia 69 (4): 404–6.  
  12. ^ Vila, P; Vallès, J; Canet, J; Melero, A; Vidal, F (November 1991). "Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.". Anaesthesia 46 (11): 967–9.  
  13. ^ Jahr, JS; Burckart, G; Smith, SS; Shapiro, J; Cook, DR (July 1991). "Effects of famotidine on gastric pH and residual volume in pediatric surgery.". Acta anaesthesiologica Scandinavica 35 (5): 457–60.  
  14. ^ 
  15. ^ Fogg TB, Semple D (29 November 2007). "Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions". BestBets. Manchester, England:  
  16. ^ Pepcid Complete
  17. ^ 
  18. ^ "Pepcid Side Effects & Drug Interactions". 2008. Retrieved 2008-07-31. 
  19. ^ US patent 4283408, HIRATA YASUFUMI; YANAGISAWA ISAO; ISHII YOSHIO; TSUKAMOTO SHINICHI; ITO NORIKI; ISOMURA YASUO; TAKEDA MASAAKI, "Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them", issued 1981-08-11 
  20. ^ "Sankyo Pharma". Skyscape Mediwire. 2002. Retrieved 2009-10-30. 
  21. ^ Howard, JM; Chremos, AN; Collen, MJ; McArthur, KE; Cherner, JA; Maton, PN; Ciarleglio, CA; Cornelius, MJ; Gardner, JD; Jensen, RT (April 1985). "Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.". Gastroenterology 88 (4): 1026–33.  
  22. ^ Retrieved 7 June 2015. 
  23. ^ "Formulation and Evaluation of Gastroretentive Floating Tablets of Famotidine". Farmavita.Net. 2008. Retrieved 2009-01-30. 
  24. ^ Meskanen, K; Ekelund, H; Laitinen, J; Neuvonen, PJ; Haukka, J; Panula, P; Ekelund, J (August 2013). "A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.". Journal of Clinical Psychopharmacology 33 (4): 472–478.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.